Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Single-blind, Multiple Dose Study to Evaluate Safety and the Effects of RL-007 on Electroencephalograms and Event-related Potentials in Subjects With Schizophrenia

Next Previous
Trial Profile

A Single-arm, Single-blind, Multiple Dose Study to Evaluate Safety and the Effects of RL-007 on Electroencephalograms and Event-related Potentials in Subjects With Schizophrenia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RL-007 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Recognify Life Sciences

Most Recent Events

  • 14 Dec 2021 Status changed from recruiting to completed, according to an ATAI Life Sciences media release.
  • 14 Dec 2021 According to an ATAI Life Sciences media release, the company will discuss trial design during a Key Opinion Leader Event, January 18, 2022.
  • 14 Dec 2021 Results presented in an ATAI Life Sciences media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top